IDiyas

For the Inventor, By the Inventor

Starnberg, Germany

Herbert Jungfer

USPTO Granted Patents = 11

Average Co-Inventor Count = 4.2

ph-index = 6

Forward Citations = 144(Granted Patents)


Location History:

  • Tutzing, DE (1988 - 1994)
  • Starnberg, DE (1997 - 2003)
  • Stabrnbert, DE (2003)

Company Filing History:

goldMedal7 out of 1,164 
 
Boehringer Mannheim Gmbh
 patents
silverMedal2 out of 480 
 
Roche Diagnostics Gmbh
 patents
bronzeMedal1 out of 1 
 
Winfried Albert
 patent
4. 1 out of 832,680 
Other
 patents

Years Active: 1988-2003

Loading Chart...
11 patents (USPTO):
1. 6576466 - Tumoricidal T lymphocytes (2003-06-10),
2. 6511848 - Process for producing and multiplying lymphocytes (2003-01-28),
3. 6503706 - Method for identifying human and animal cells having an unlimited proliferation of tumor-formation potential (2003-01-07),
4. 6214568 - Monoclonal antibodies of isotype IgG which bind specifically to glutamate decarboxylase, and uses thereof (2001-04-10),
5. 5888813 - Monoclonal antibodies against human pancreatic islet cells (1999-03-30),
6. 5674723 - Nucleic acid molecules which immortalize human or animal cells and uses (1997-10-07),
7. 5610280 - Monoclonal antibodies against melanoma (1997-03-11),
8. 5286646 - Method for mammalian cell culture (1994-02-15),
9. 5114847 - Process for the production of permanently culturable animal and human (1992-05-19),
10. 4939082 - Process and monoclonal antibody for the specific determination of (1990-07-03),
11. 4742159 - Digitalis antibodies, process for the preparation thereof and the use (1988-05-03),

Title: Herbert Jungfer: Innovator in Tumor Therapy

Introduction

Herbert Jungfer is a notable inventor based in Starnberg, Germany. He has made significant contributions to the field of immunology, particularly in the development of therapeutic agents for tumor therapy. With a total of 11 patents to his name, Jungfer's work has had a profound impact on cancer treatment methodologies.

Latest Patents

Among his latest patents, Jungfer has developed a method for producing tumoricidal T lymphocytes. This invention involves a mammalian cell line that, when co-cultured with lymphocytes while avoiding allogenic stimulation, activates these lymphocytes to form tumoricidal cells. Additionally, he has patented a process for culturing and multiplying lymphocytes using a cell culture medium enriched with lymphocyte growth factors, including aurin tricarboxylic acid, ciclosporin, tacrolimus, and ascomycin. These innovations are crucial for advancing therapeutic strategies in tumor therapy.

Career Highlights

Throughout his career, Jungfer has worked with prominent companies in the pharmaceutical and diagnostics sectors. Notably, he has been associated with Boehringer Mannheim GmbH and Roche Diagnostics GmbH. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research in immunotherapy.

Collaborations

Jungfer has collaborated with esteemed colleagues, including Winfried Albert and Heinrich Barchet. These partnerships have facilitated the exchange of ideas and fostered innovation in their respective fields.

Conclusion

Herbert Jungfer's contributions to the field of tumor therapy through his innovative patents and collaborations highlight his role as a leading inventor in immunology. His work continues to inspire advancements in cancer treatment and therapeutic development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…